Janus Kinase inhibitors (JAKi) – IMF – Recommendations to mitigate serious safety concerns
01/03/2023
Medicines for human use
Safety update
This article was produced by the HPRA for publication in the March 2023 edition of Irish Medicines Formulary (IMF) and describes recommendations to mitigate risks of malignancy, major adverse cardiovascular events, serious infections, venous thromboembolism and mortality when used in the treatment of chronic inflammatory disorders.